Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:17:54 EDT Tue 15 Jul 2025
Enter Symbol
or Name
USA
CA



Q:BBIO - BRIDGEBIO PHARMA INC - https://bridgebio.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BBIO - Q0.146.50·46.995.046.965-0.725-1.52,416.5112,25125,39148.19  48.4153  46.6346.80  21.7216:39:00Jun 3015 min RT 2¢

Recent Trades - Last 10 of 25391
Time ETExPriceChangeVolume
16:39:00Q46.50-1.19100
16:30:14Q46.965-0.7254,623
16:29:59Q47.00-0.6924
16:24:25Q46.965-0.7252
16:20:00Q46.965-0.725475
16:17:05Q46.99-0.701
16:10:47Q46.97-0.7221,893
16:09:42Q46.97-0.728,007
16:09:30Q46.97-0.7221,893
16:09:29Q46.50-1.191

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-30 07:30U:BBIONews ReleaseBridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA(TM) European Royalty
2025-06-26 07:30U:BBIONews ReleaseBridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
2025-06-02 07:30U:BBIONews ReleaseBridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
2025-05-20 07:30U:BBIONews ReleaseAcoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
2025-05-19 12:34U:BBIONews ReleaseEarly and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
2025-05-14 16:01U:BBIONews ReleaseBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2025-05-13 07:30U:BBIONews ReleaseFirst Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
2025-05-12 07:30U:BBIONews ReleaseBridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
2025-05-07 07:30U:BBIONews ReleaseBridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
2025-04-29 16:01U:BBIONews ReleaseBridgeBio Reports First Quarter 2025 Financial Results and Business Updates
2025-04-28 05:00U:BBIONews ReleaseBEYONTTRA(TM) (acoramidis), the First Near-complete TTR Stabilizer (>=90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM
2025-04-22 07:31U:BBIONews ReleaseBridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET
2025-04-11 16:01U:BBIONews ReleaseBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2025-03-31 10:00U:BBIONews ReleaseAcoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
2025-03-27 07:00U:BBIONews ReleaseBeyonttra(TM) (acoramidis), the First Near-complete TTR Stabilizer (>=90%), Approved in Japan to Treat ATTR-CM
2025-03-24 07:30U:BBIONews ReleaseBridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions
2025-03-21 16:00U:BBIONews ReleaseBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2025-03-17 16:01U:BBIONews ReleaseBridgeBio Announces CFO Succession
2025-02-26 02:50U:BBIONews ReleaseBridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt
2025-02-24 16:10U:BBIONews ReleaseBridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt